Since both KLF5 and ATBF-1 were shown to suppress estrogen signaling in breast cancer cells [27,28], Efp is suggested to promote breast cancer by enhancing estrogen receptor signaling (Figure 1). The gene discussed is KLF5; the disease is breast carcinoma.